The shadow of generic challenges has repeatedly loomed above copyright’s famous drug, Sildenafil, sparking questions about the future of connected medicinal portfolios. While initial years saw substantial returns, the exclusivity end has created the path for less expensive copies, likely reducing profitability and posing a real danger for stakeh… Read More